)
Scientific Industries (SCND) investor relations material
Scientific Industries Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Revenue for Q2 2026 increased 36% year-over-year to $1.47M, driven by higher Benchtop Laboratory Equipment and Bioprocessing Systems sales.
Gross margin improved to 42.3% from 34.8% year-over-year, reflecting a favorable product mix and higher-margin DOTS product sales.
Operating loss narrowed to $1.27M from $1.82M in Q2 2025, aided by cost reductions in G&A and selling expenses.
Net loss from continuing operations was $1.23M for Q2 2026, with discontinued operations contributing $273K in income.
The Genie Division sale in August 2025 continues to impact results, with ongoing transition and supply agreements.
Financial highlights
Q2 2026 revenue: $1.47M (up from $1.08M in Q2 2025); six-month revenue: $2.70M (up from $2.02M year-over-year).
Gross profit margin: 42.3% in Q2 2026 vs. 34.8% in Q2 2025; six-month margin: 40.5% vs. 35.6%.
Operating expenses for Q2 2026: G&A $553.9K, Selling $647.1K, R&D $694.5K.
Net loss for Q2 2026: $1.20M; six-month net loss: $2.87M.
Cash and equivalents at June 30, 2026: $616.5K; investment securities: $3.93M.
Outlook and guidance
Management expects continued negative cash flows from operations due to ongoing investment in Bioprocessing Systems.
Cash from the Genie Division sale and related agreements is expected to support operations for at least one year.
No formal revenue or earnings guidance provided.
- Revenue rose 30% and net loss narrowed, but ongoing negative cash flow remains a concern.SCND
Q1 2026 - 2025 net loss shrank to $1.22M as Genie Division sale offset ongoing bioprocessing losses.SCND
Q4 2025 - Annual meeting to vote on director elections, equity plan amendment, and auditor ratification.SCND
Proxy Filing - Registering 3.1M shares for resale, company faces losses, liquidity risks, and bioprocessing focus.SCND
Registration Filing - Bioprocessing-focused growth strategy drives losses; 8M-share resale offering targets capital needs.SCND
Registration Filing - 3.1M shares registered for resale as company pivots to bioprocessing amid ongoing losses.SCND
Registration Filing - Net loss narrowed and sales rose, but liquidity and going concern risks remain.SCND
Q3 2024 - Net loss narrowed and margins improved, but liquidity and funding remain critical concerns.SCND
Q2 2024 - Bioprocessing sales rose 24% in 2024, with cost cuts and a strong pipeline for 2025.SCND
Q4 2024
Next Scientific Industries earnings date
Next Scientific Industries earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)